Document:

EX-10.8

 Exhibit 10.8 

MERIDIAN BIOSCIENCE, INC. 

2012 STOCK INCENTIVE PLAN 

NONQUALIFIED STOCK OPTION AGREEMENT 

Summary of Nonqualified Stock Option Grant 

Meridian Bioscience, Inc., an Ohio corporation (the “Company”), grants to the Grantee named below, in
accordance with the terms of the Meridian Bioscience, Inc. 2012 Stock Incentive Plan, a copy of which is available on the Bank of America Merrill Lynch website at www.benefits.ml.com (the “Plan”) and this Nonqualified Stock Option
Agreement (the “Agreement”), an option to purchase Shares of the Common Stock of the Company at an exercise price per Share as described below: 
  

							
		 	 Name of Grantee:
	  	                                     
                       	  	
				
	         
	 	 Number of Underlying Shares:
	  	                                     
            	  	
				
		 	 Exercise Price Per Share:
	  	                                     
            	  	
				
		 	 Grant Date:
	  	        November 5th, 2020         	  	
				
		 	 Vesting Date:
	  	        November 15th, 2023       	  	
				
		 	 Expiration Date:
	  	        November 5th, 2030         	  	

 Terms of Agreement 

1.        Grant of Nonqualified Stock Option. Subject to and upon the
terms, conditions, and restrictions set forth in this Agreement and in the Plan, the Company hereby grants to the Grantee as of the Grant Date, an option to purchase Shares of Common Stock of the Company at an exercise price per Share as set forth
above (the “Option”). It is the intent of the Company and the Grantee that the Option will not qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended from time to
time. 
 2.        Vesting of Option. 

           (a)        Except
as otherwise provided in this Agreement, the Option shall become exercisable according to the vesting schedule set forth above. 

           (b)        The
Option shall vest in full prior to the Vesting Date(s) upon the occurrence of any of the following: (i) the Grantee dies while in the employ of the Company; (ii) the Grantee satisfies the requirements for Retirement, as defined in the
Plan, including separation from employment with the Company; (iii) the Grantee has a Disability, as defined in the Plan; or (iv) there is a Change in Control event described in Section 2(g) of the Plan. The Option shall be exercisable
for ninety days following the occurrence of the condition described in Section 2(b)(ii). The Option shall be exercisable for one year following the occurrence of the conditions described in Sections 2(b)(i) and 2(b)(iii). 

           (c)        The
Committee may, in its sole discretion, accelerate the time at which the Option becomes vested and non-forfeitable to a time other than the Vesting Date(s) as provided in Section 2(a) or to a time other
than provided in Section (2)(b)(i), (ii), (iii) or (iv) on such terms and conditions as it deems appropriate in accordance with the terms and conditions of the Plan. 

 3.        Forfeiture of
Option. Any portion of the Option that has not yet vested pursuant to Section 2 shall be forfeited automatically without further action or notice if the Grantee ceases to be employed by the Company other than as provided in
Section 2(b) or (c) hereof. 
 4.        Exercise and Payment.

           (a)        The
Option granted under this Agreement shall be exercisable on the Vesting Date(s) as provided on the first page under “Summary of Nonqualified Stock Option Grant” herein. The Option granted under this Agreement may not be exercised as to
less than twenty-five (25) Shares at any time. 

           (b)        The
Option may be exercised for the number of Shares specified by Grantee’s delivery of instructions through and in accordance with the procedures established under the Merrill Lynch system maintained on behalf of the Company, accompanied by full
payment in the manner and subject to the conditions set forth pursuant to the terms of the Plan for the number of Shares in respect of which it is exercised. The Grantee may pay the Exercise Price by means of a broker-assisted “cashless
exercise” pursuant to which the Company or Merrill Lynch, as the case may be, is delivered a copy of irrevocable instructions to a stockbroker to sell the Shares of Common Stock otherwise deliverable upon the exercise of the Option and to
deliver promptly to the Company an amount equal to the Exercise Price and/or the amount of any taxes described in Section 10 below (“Broker-Assisted Cashless Exercise”). Any fractional Share of Common Stock may be settled in
cash in a Broker-Assisted Cashless Exercise. 

           (c)        If any
applicable law or regulation requires the Company to take any action with respect to the Shares specified in such notice, or if any action remains to be taken under the Articles of Incorporation or Code of Regulations of the Company to effect due
issuance of the Shares, then the Company shall take such action and the day for delivery of such stock shall be extended for the period necessary to take such action. 

5.        Transferability.    The Option
may not be transferred and shall not be subject in any manner to assignment, alienation, pledge, encumbrance or charge, unless otherwise provided under the Plan. Any purported Transfer or encumbrance in violation of the provisions of this
Section 5 shall be void, and the other party to any such purported transaction shall not obtain any rights to or interest in the Option. 

6.        Voting and Other Rights. The Grantee will not have any
rights of a shareholder of the Company with respect to the Option until the delivery of the underlying Shares into which the Option is exercised. 

7.        Continuous Employment. Unless otherwise specified by the
Plan, for purposes of this Agreement, the continuous employment of the Grantee with the Company shall not be deemed to have been interrupted, and the Grantee shall not be deemed to have ceased to be an employee of the Company, by reason of the
transfer of his employment among the Company or a leave of absence approved by the Committee. 

8.        No Employment Contract. Nothing contained in this Agreement
shall confer upon the Grantee any right with respect to continuance of employment by the Company, nor limit or affect in any manner the right of the Company to terminate the employment or adjust the compensation of the Grantee. 

9.        Relation to Other Benefits. Any economic or other benefit to
the Grantee under this Agreement or the Plan shall not be taken into account in determining any benefits to which the Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained by the Company and
shall not affect the amount of any life insurance coverage available to any beneficiary under any life insurance plan covering employees of the Company.  

10.        Taxes and Withholding. By his or her acceptance of this
Agreement, the Grantee agrees to reimburse the Company for any taxes required by any government to be withheld or otherwise deducted and paid by the Company with respect to the issuance or disposition of the Shares subject to the Option. In lieu

  
 - 2 - 

 
thereof, the Company shall have the right to withhold the amount of such taxes from any other sums due or to become due from the Company to the Participant. The Company may, in its discretion,
hold the stock certificate or certificates to which the Grantee is entitled upon the exercise of the Option as security for the payment of such withholding tax liability, until cash sufficient to pay that liability has been accumulated. In addition,
at any time that the Company becomes subject to a withholding obligation under applicable law with respect to the exercise of the Option (the “Tax Date”), except as set forth below, a holder of the Option may elect to satisfy, in
whole or in part, the holder’s related personal tax liabilities (an “Election”) by (a) directing the Company to withhold from Shares issuable in the related exercise either a specified number of Shares or Shares having a
specified value (in each case not in excess of the minimum required tax withholding amount), (b) tendering Shares previously issued pursuant to the exercise of an Award or other Shares owned by the holder, (c) executing a Broker-Assisted
Cashless Exercise, or (d) combining any or all of the foregoing Elections in any fashion. An Election shall be irrevocable. The withheld Shares and other Shares tendered in payment shall be valued at their Fair Market Value on the Tax Date. The
Committee may disapprove of any Election, suspend or terminate the right to make Elections or provide that the right to make Elections shall not apply to particular Shares or exercises. The Committee may impose any additional conditions or
restrictions on the right to make an Election as it shall deem appropriate, including any limitations necessary to comply with Section 16 of the Exchange Act.  

11.        Adjustments. The number and kind of Shares deliverable
pursuant to the Option are subject to adjustment as provided in Section 8 of the Plan.  

12.        Compliance with Law. While the Company shall make
reasonable efforts to comply with all applicable federal and state securities laws and listing requirements with respect to the Shares that may be delivered pursuant hereto, the Company shall not be obligated to deliver any Shares pursuant to this
Agreement if the delivery thereof would result in a violation of any such law or listing requirement. 

13.        Amendments. Subject to the terms of the Plan, the Committee
may modify this Agreement upon written notice to the Grantee. Any amendment to the Plan shall be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto. 

14.        Severability. In the event that one or more of the
provisions of this Agreement shall be invalidated for any reason by a court of competent jurisdiction, any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue
to be valid and fully enforceable. 
 15.        Relation to Plan.
This Agreement is subject to the terms and conditions of the Plan. This Agreement and the Plan contain the entire agreement and understanding of the parties with respect to the subject matter contained in this Agreement, and supersede all prior
written or oral communications, representations and negotiations in respect thereto. In the event of any inconsistency between the provisions of this Agreement and the Plan, the Plan shall govern except with respect to Section 2(a) of this
Agreement. Capitalized terms used herein without definition shall have the meanings assigned to them in the Plan. The Committee acting pursuant to the Plan, as constituted from time to time, shall, except as expressly provided otherwise herein, have
the right to determine any questions which arise in connection with the grant of the Option. 

16.        Successors and Assigns. Without limiting Section 5,
the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of the Grantee, and the successors and assigns of the Company. 

17.        No Advice Regarding Award. The Company is not
providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Grantee’s participation in the Plan or the acquisition or sale of the underlying securities. The Grantee is hereby advised to consult with
the Grantee’s personal tax, legal or financial advisors regarding the decision to participate in the Plan before taking any action related to the Plan. 

  
 - 3 - 

 18.        Governing Law.

           (a)        The
interpretation, performance, and enforcement of this Agreement, including tort claims, shall be governed by the laws of the State of Ohio, without giving effect to the principles of conflict of laws thereof. 

           (b)        Any
party bringing a legal action or proceeding against another party arising out of or relating to this Agreement may bring the legal action or proceeding only in the United States District Court for the Southern District of Ohio and any of the courts
of the State of Ohio, in each case sitting in Cincinnati, Ohio. 

           (c)        Each of
the Company and the Grantee waives, to the fullest extent permitted by law, (i) any objection which it may now or later have to the laying of venue of any legal action or proceeding arising out of or relating to this Agreement brought in any
court of the State of Ohio sitting in Cincinnati, Ohio or the United States District Court for the Southern District of Ohio sitting in Cincinnati, Ohio, including, without limitation, a motion to dismiss on the grounds of forum non
conveniens or lack of subject matter jurisdiction; and (ii) any claim that any action or proceeding brought in any such court has been brought in an inconvenient forum. 

           (d)        Each of
the Company and the Grantee submits to the exclusive jurisdiction (both personal and subject matter) of (i) the United States District Court for the Southern District of Ohio sitting in Cincinnati, Ohio and its appellate courts, and
(ii) any court of the State of Ohio sitting in Cincinnati, Ohio and its appellate courts, for the purposes of all legal actions and proceedings arising out of or related to this Agreement. 

19.        Language. If the Grantee receives this Agreement or any
other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control. 

20.        Electronic Delivery. The Grantee hereby consents and agrees
to electronic delivery of any documents that the Company may elect to deliver (including, but not limited to, prospectuses, prospectus supplements, grant or award notifications and agreements, account statements, annual and quarterly reports, and
all other forms of communications) in connection with this and any other award made or offered under the Plan. The Grantee understands that, unless earlier revoked by the Grantee by giving written notice to the Secretary of the Company, this consent
shall be effective for the duration of the Agreement. The Grantee also understands that he or she shall have the right at any time to request that the Company deliver written copies of any and all materials referred to above at no charge. The
Grantee hereby consents to any and all procedures the Company has established or may establish for an electronic signature system for delivery and acceptance of any such documents that the Company may elect to deliver, and agrees that his or her
electronic signature is the same as, and shall have the same force and effect as, his or her manual signature. The Grantee consents and agrees that any such procedures and delivery may be effected by a third party engaged by the Company to provide
administrative services related to the Plan. 
 IN WITNESS WHEREOF, the Company has caused this Agreement to be executed
on its behalf by its duly authorized officer and the Grantee has also executed this Agreement, as of the Grant Date. 
  

			
	MERIDIAN BIOSCIENCE, INC.	  	
		
	By:                                     
                       	  	        
	Name: Bryan T. Baldasare	  	
	Title: Chief Financial Officer	  	

  
 - 4 -EX-10.16

 Exhibit 10.16 

AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT 

This AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT dated as of September 29, 2020, is entered into between APRÈS-DEMAIN DIAGNOSTICS INC. (formerly known as Genepoc Inc.), a corporation incorporated under the laws of Canada (“Seller”), MERIDIAN BIOSCIENCE CANADA INC., a corporation incorporated
under the laws of British Columbia (“Buyer”), APRÈS-DEMAIN SA (formerly known as APRÈS-DEMAIN HOLDING SA), in its capacity of
Shareholders’ Representative, and MERIDIAN BIOSCIENCE, INC. 
 RECITALS 

WHEREAS on April 29, 2019, a share purchase agreement (as amended by that Amendment to Share Purchase Agreement
dated June 3, 2019, the “Purchase Agreement”) was entered into between the Seller, Meridian Bioscience Canada Inc. (a predecessor by amalgamation of Buyer), the Shareholders solely for the purpose of Sections 5.03, 8.01 and
10.05 thereof, Après-Demain SA (formerly known as Après-Demain Holding SA) solely in its capacity of Shareholders’ Representative, and Meridian Bioscience, Inc., solely for the purpose of Sections 2.06,
2.07 and 8.02 thereof, pursuant to which Meridian Bioscience Canada Inc. (a predecessor by amalgamation of Buyer) agreed to purchase, on the Closing Date (as such term is defined in the Purchase Agreement) and the Seller agreed
to sell, all of the shares held by Seller in the share capital of Genepoc Canada Inc. (defined in the Purchase Agreement as the “Company”) as of the Closing Date; 

WHEREAS Meridian Bioscience Canada Inc. (a predecessor by amalgamation of Buyer) and the Company amalgamated on
June 3, 2019, to continue as the Buyer; 
 WHEREAS by Section 10.05 of the Purchase
Agreement, Après-Demain SA was appointed as “Shareholders’ Representative” whereby it can act as “agent, proxy and attorney-in-fact for”
each Shareholder in order, among other matters, “(b) to execute and deliver on behalf of such Shareholder any amendment or waiver hereto, (c) to take all other actions to be taken by or on behalf of such Shareholder in connection
herewith”; 
 WHEREAS by Section 10.10 of the Purchase Agreement, the Purchase Agreement “may
only be amended, modified or supplemented by an agreement in writing signed by Buyer, Seller and Shareholders’ Representative”; 

WHEREAS pursuant to Sections 2.05(a) and 2.05(b) of the Purchase Agreement, the Buyer agreed to make two
(2) payments to the Seller under the Promissory Note (as such term is defined in the Purchase Agreement), subject to the Buyer’s satisfaction of certain conditions, including (i) a Premarket Notification Submission (as such term is
defined in the Purchase Agreement) by Buyer or the Company or any of their Affiliates related to the GI Panel Assay (as such term is defined in the Purchase Agreement) on or before September 30, 2020, and (ii) a Premarket Notification
Submission (as such term is defined in the Purchase Agreement) by Buyer or the Company or any of their Affiliates related to the RI Panel Assay (as such term is defined in the Purchase Agreement) on or before March 31, 2021 (together, the
“Regulatory Milestones”); 

 WHEREAS the Buyer and the Seller have agreed to certain changes to the
Regulatory Milestones, and have agreed to extend the due dates of the Regulatory Milestones and to adjust any payments due to Buyer under Sections 2.05(a) and 2.05(b) as set forth herein; 

WHEREAS Schedule 2 to the Purchase Agreement provides, among other things, a description of the RI Panel Assay
including the description of the assay specifications relating to the RI Viral Panel under development by the Seller; 

WHEREAS the Seller and the Buyer have also reached an agreement to revise the RI Viral Panel as described on Schedule 2
to the Purchase Agreement; and 
 WHEREAS the parties hereto therefore wish to amend the Purchase Agreement as of and from
the date hereof in order to reflect, amongst others, the above mentioned agreements as well as other changes arising therefrom or related thereto. 

NOW THEREFORE, in consideration of the premises and mutual agreements herein contained, and for other good and valuable
consideration (the receipt and sufficiency of which are acknowledged by each party), the parties hereto agree as follows: 

ARTICLE 1 

INTERPRETATION 
  

	1.1	 Definitions 

In this Amendment No. 2 (as defined below), all defined terms shall have the meanings ascribed thereto in the Purchase
Agreement, unless otherwise defined herein. 
 ARTICLE 2 

AMENDMENT TO PURCHASE AGREEMENT 
  

	2.1	 Amendment to Article I - Definitions 

(i)    Two additional definitions shall be added to Article I of the Purchase Agreement
which state the following: 
 “Amendment No. 2” means the Amendment No. 2 to Share
Purchase Agreement dated September 29, 2020 by and between Seller, Buyer, Shareholders’ Representative and Meridian ParentCo.” 

“FDA Clearance” means a clearance issued by the FDA respectively for the GI Panel Assay or the GI Panel
Assay, after review and approval of the Premarket Notification Submission of the GI Panel Assay or the RI Panel Assay, as applicable, under Section 510(k) of the U.S. Food, Drug and Cosmetic Act and 21 CFR § 807.100 et
seq., or any equivalent clearance that may replace this clearance.” 
 (ii)    The definitions
“Regulatory Milestone Plan” and “Commercially Reasonable Efforts” are hereby deleted and replaced by the following: 

  
 - 2 - 

 “Commercially Reasonable Efforts” shall mean, for the
purposes of Section 2.07, with respect to the efforts and resources to be expended, or considerations to be undertaken, by Buyer and its Affiliates such reasonable, diligent and good faith continuous efforts and resources,
consistent with applicable Laws, as a fully integrated diagnostic and life science company of a similar size and with similar revenues as Buyer and its Affiliates would normally use to accomplish a similar objective, activity or decision under
similar circumstances, it being understood and agreed that with respect to the marketing, manufacture, seeking and obtaining regulatory approval, or commercialization of any product or product candidate, such efforts and resources shall be
consistent with those efforts and resources commonly used by such a fully integrated diagnostic and life science company under similar circumstances for a similar product or product candidate owned by it, or to which it has similar rights, which
product or product candidate is at a similar stage in its development or product life and is of similar market potential (taking into account all relevant factors, including: (i) issues of efficacy, safety, and expected and actual approved
instructions for use, (ii) the expected and actual competitiveness of alternative products sold by third parties or Meridian ParentCo or any of its Affiliates in the marketplace, (iii) the expected and actual product performance,
(iv) the expected and actual patent and other proprietary position of the product(s) or product candidate(s), (v) the likelihood and difficulty of obtaining regulatory approval given the regulatory structure involved, (vi) pending, actual
or threatened legal proceedings with respect to the product(s) or product candidate(s), (vii) input from regulatory experts and any guidance or developments from the FDA, Health Canada or similar Governmental Authority affecting the data required in
order to make a Premarket Notification Submission, or to obtain clearance from the FDA under Section 510(k) of the U.S. Food, Drug and Cosmetic Act or to obtain similar clearance from or approval by any other Governmental Authority,
(viii) compliance with Healthcare Laws, (ix) the expected and actual profitability and return on investment of the product(s) or product candidate(s) taking into consideration, among other factors (x) third party costs and expenses
incurred in the development of such product, (y) royalty, milestone and other payments owed based on the commercialization of such product (but not taking into account any amounts owed under this Agreement), and (z) expected and actual
pricing and reimbursement relating to the product(s) or product candidate(s)), provided, in any event, that (i) with respect to the objective related to the Regulatory Earnout, the preparation for and the filing of the Premarket Notification
Submissions for the GI Panel Assay and RI Panel Assay, shall be made consistent with the exercise of Buyer’s prudent scientific judgment, of diligent efforts and resources to fulfill the obligation in issue, consistent with the level of efforts
Buyer would normally devote to its own Premarket Notification Submissions for its product at a similar stage in its product life as the GI Panel Assay and the RI Panel, taking into account scientific, regulatory factors, and the safety and efficacy
of the GI Panel Assay and RI Panel Assay, all based on conditions prevailing at the time such efforts are due, but provided that the Covid 19 pandemic for the period through the date of this Amendment No. 2 only, shall not be taken into account
in order to determine if the Buyer or its Affiliates took their Commercially Reasonable Efforts and shall not be an element justifying the fact that the Regulatory Milestone may eventually not be met, and (ii) with respect to the objective
related to the Gross Sales Earnout and Gross Margin Target, the application by Buyer, consistent with 

  
 - 3 - 

 
the exercise of its business judgement, of diligent efforts and resources to fulfill the obligation in issue, consistent with the level of efforts Buyer would normally devote to its own branded
product of comparable commercial value at a similar stage in its product life as the Specified Products, taking into account competitive market conditions in the diagnostics solutions area, all based on conditions prevailing at the time such efforts
are due. For greater certainty and without limiting the generality of the preceding, the parties agree that the fact that the design and development of the Revogene platform (the “Redesign Work”) and assays set forth in Schedule
1.01, which the Seller represents to be of a sufficient level of development to be completed on or before July 31, 2019, shall not be taken into account to determine if the Buyer complied with its obligations to make its Commercially
Reasonable Efforts to achieve the First Regulatory Milestone or Second Regulatory Milestone or to maximize the Gross Sales Earnout if the delay or failure is related to the fact that the Redesign Work is not completed by July 31, 2019.”

 “Regulatory Plan” has the meaning set forth in Section 2.05(d).” 

All references to “Regulatory Milestone Plan” in the Purchase Agreement shall now refer to the
“Regulatory Plan.” 
  

	2.2	 Replacement of Schedule 2 of the Purchase Agreement 

Schedule 2 to the Purchase Agreement is hereby deleted in its entirety and replaced by the revised and amended
Schedule 2 attached hereto. All references to Schedule 2 in the Purchase Agreement, including in the definitions of GI Panel Assay and RI Panel Assay shall refer to the revised and amended Schedule 2 attached to this Amendment
No. 2. 
  

	2.3	 Amendment of Section 2.02 

Section 2.02 of the Purchase Agreement is hereby deleted in its entirety and replaced by the following: 

“2.02    Purchase Price. 

(a)        The aggregate purchase price for the Purchased Shares (the
“Purchase Price”) shall be (i) Fifty Million Dollars ($50,000,000), subject to the adjustment set forth in Section 2.08 hereof (the “Base Cash Payment”) plus (ii) Fourteen Million Dollars
($14,000,000) subject to the adjustment set forth in Section 2.05 (the “Regulatory Earnout”, together with the Base Cash Payment, the “Base Purchase Price”), plus (iii) the Gross Sales
Earnout which shall be paid (if at all) pursuant to Section 2.06(a). 

(b)        The Base Purchase Price shall be payable as follows: 

(i)        by the payment of the Base Cash Payment, as adjusted pursuant to
Section 2.08(a), less the Holdback Amount, at the Closing, by wire transfer of immediately available funds, as set forth in Section 2.04(a)(i) and Section 2.04(a)(ii); and 

  
 - 4 - 

 (ii)        by the issuance, to the
Seller, at the Closing of a non-interest bearing term promissory note in the form attached hereto as Exhibit E in the amount of the Regulatory Earnout (the “Promissory Note”), as amended in
accordance with Section 2.3 of this Amendment No. 2 to Share Purchase Agreement.” 
  

	2.4	 Amendment of Section 2.05(a)  

Section 2.05(a) of the Purchase Agreement is hereby deleted in its entirety and replaced by the
following: 
 “(a)     An amount equal to Four Million Dollars ($4,000,000.00) (the
“First Regulatory Milestone Payment”) shall be due and payable by the Buyer under the Promissory Note, following FDA Clearance of the GI Panel Assay, provided that such FDA Clearance of the GI Panel Assay occurs on or before
September 30, 2022 (the “First Regulatory Milestone”). Buyer shall pay Seller this amount, if the First Regulatory Milestone is met, within thirty (30) days of receipt by Buyer or any of its Affiliates of such FDA
Clearance; provided, however that in the event the First Regulatory Milestone is not met, the capital amount of the Promissory Note shall be deemed reduced by an amount equal to the First Regulatory Milestone Payment as of October 1st, 2022. Seller and Buyer agree that the September 30, 2022 date for the First Regulatory Milestone is a firm and definitive date, and such date shall not be further extended under any
circumstances; and” 
  

	2.5	 Amendment of Section 2.05(b) 

Section 2.05(b) of the Purchase Agreement is hereby deleted in its entirety and replaced by the
following: 
 “(b)    Another amount equal to Ten Million Dollars ($10,000,000) (the
“Second Regulatory Milestone Payment”) shall be due and payable by the Buyer under the Promissory Note, following FDA Clearance of the RI Panel Assay, provided that such FDA Clearance of the RI Panel Assay occurs on or before
September 30, 2022 (the “Second Regulatory Milestone”). Buyer shall pay Seller this amount, if the Second Regulatory Milestone is met, within thirty (30) days of receipt by Buyer or any of its Affiliates of such FDA
Clearance; provided, however that in the event the Second Regulatory Milestone is not met, the capital amount of the Promissory Note shall be deemed reduced by an amount equal to the Second Regulatory Milestone Payment as of October 1st, 2022; further provided, that in the event that neither the First Regulatory Milestone nor the Second Regulatory Milestone are met, the Promissory Note shall be deemed cancelled and of no
further effect as of October 1st, 2022. Seller and Buyer agree that the September 30, 2022 date for the Second Regulatory Milestone is a firm and definitive date, and such date shall not be
further extended under any circumstances.” 

  
 - 5 - 

	2.6	 Deletion of Section 2.05(c) 

Section 2.05(c) of the Purchase Agreement is hereby deleted in its entirety and shall be of no
further force and effect. 
  

	2.7	 Replacement of Schedule 4 of the Purchase Agreement 

Schedule 4 to the Purchase Agreement is hereby deleted in its entirety and replaced by the revised and amended
Schedule 4 attached hereto. All references to Schedule 4 in the Purchase Agreement shall refer to the revised and amended Schedule 4 attached to this Amendment No. 2. 

 

	2.8	 Amendment of Section 2.05(d) 

Section 2.05(d) of the Purchase Agreement is hereby deleted in its entirety and replaced by the
following: 
 “(d) A non-binding plan for the achievement of
the First Regulatory Milestone and Second Regulatory Milestone developed in good faith by Buyer and Seller is attached hereto as Schedule 4 (the “Regulatory Plan”). Buyer hereby warrants and represents that as of the
date of this Amendment No. 2 it has no knowledge of any fact or circumstances that is reasonably likely to make the Regulatory Plan as revised pursuant to this Amendment No. 2 unachievable by Buyer to
meet the First Regulatory Milestone and the Second Regulatory Milestone. During the period beginning as of the date of this Amendment No. 2 and ending upon the full payment or cancellation of the Promissory Note, Buyer
shall provide Seller with quarterly reports detailing Buyer’s progress towards achievement of the First Regulatory Milestone and Second Regulatory Milestone in accordance with the Regulatory Plan or any revised Regulatory Plan, as
applicable, in substantially the form and content as set forth on Exhibit B attached hereto. If Buyer’s report indicates a material departure from the Regulatory Plan, the report shall also include a revised non-binding Regulatory Plan developed by Buyer in good faith and describing Buyer’s good faith plan for achieving the First Regulatory Milestone and Second Regulatory Milestone despite the material departure
from the original Regulatory Plan. For the avoidance of doubt and without limiting the other obligations of Buyer and its Affiliates under this Agreement, Buyer’s failure or inability to comply with the Regulatory Plan attached hereto or as
revised shall not be deemed a breach of Buyer’s obligations under this Agreement provided that if the Regulatory Plan is not met as a result of the Covid-19 pandemic Buyer shall provide information
available to Buyer as reasonably requested by the Seller to assess the impact of the Covid-19 pandemic on the achievement of the First Regulatory Milestone and/or Second Regulatory Milestone. ” 

 

	2.9	 Amendment to Section 2.07(c) 

Section 2.07(c) of the Purchase Agreement is hereby deleted in its entirety and replaced by the
following: 

  
 - 6 - 

 “(c)    In order to maximize the
possibility for the achievement and full payment of the Regulatory Earnout, in accordance with Section 2.05 above, from the Closing Date until the satisfaction or cancellation of the Promissory Note the Buyer undertakes and
covenants in favor of the Seller and acknowledges that the Seller is relying upon such undertakings and covenants to complete the transactions: 

(i)    to, and cause its Affiliates (including, without limitation, the Company) to
operate its business in Commercially Reasonable Efforts with respect to achievement of the Regulatory Earnout; provided, however, the obligation of Buyer to use or cause its Affiliates to use Commercially Reasonable Efforts shall not be deemed a
guarantee or assurance of kind that the Regulatory Earnout will be earned or paid; 

(ii)    not to change the specifications of the RI Panel Assay and the GI Panel Assay set
forth in Schedule 2, respectively, unless such change is required to secure the approval of any Governmental Authority and approved by Seller; 

(iii)    to use commercially reasonable efforts to secure all financings necessary for the
operation of Meridian ParentCo; 
 (iv)    not to and to cause Meridian ParentCo not to
initiate any voluntary proceedings under applicable bankruptcy and insolvency laws and similar laws affecting creditors’ rights generally; 

(v)    not to proceed with the sale, assignment, lease or exchange of all or substantially
all of the assets of the Company as of the date hereof to a third party not affiliated with the Buyer or its Affiliates without Seller’s consent, which consent will not be unreasonably withheld, conditioned or delayed (it being acknowledged
that the Company and Buyer intend to amalgamate on or shortly after Closing), and provided the acquiring third party undertakes to be bound by the terms of this Agreement related to the Regulatory Milestones, including to the payment of the
Regulatory Milestones, in a form acceptable to the Buyer acting reasonably; for greater certainty any Affiliates of the Company who intends to dispose of all or substantially all of the assets of the Company as of the date hereof will be bound by
the same obligation as set forth in this paragraph; 
 (vi)     to keep as a priority of
the development plan for the Revogene platform of the Buyer and its Affiliates the GI Panel Assay and the RI Panel Assay and not prioritize any other assays than these assays for use with the Revogene platform before the earlier of the date a FDA
Clearance is issued for both the GI Panel Assay and the RI Panel Assay or October 1, 2022; and 
 (vii)
    not to substitute the GI Panel Assay or the RI Panel Assay for other assays or combine the RI Panel Assay or the GI Panel Assay with other assays unless otherwise mutually agreed; 

  
 - 7 - 

 provided that, in the event that any transaction or restriction set forth in
this Section 2.07(c) occurs or is breached, the Buyer shall pay to the Seller the full amount of the Regulatory Earnout within ten (10) Business Days following any such occurrence. 

 

	2.10	 Amendment of Section 10.02 

Section 10.02 shall be amended in order to delete the reference to Après-Demain Holding SA
for a reference to Après-Demain SA. 
 Section 10.02 shall be amended in order to delete
the reference to the address of Après-Demain SA at Rue du Levant 146, Campus “après-demain” 1920 Martigny, Switzerland for a reference to “Chemin Messidor 5-7, Forum
“après-demain”, 1006 Lausanne, Switzerland. 
  

	2.11	 Amendment and Restatement of Promissory Note 

The Promissory Note executed at Closing is hereby amended and restated in the form of Exhibit A to this Amendment
No. 2. Seller will execute and deliver to Buyer such amended and restated Promissory Note contemporaneously with the execution of this Amendment No. 2. 
  

	2.12	 Effect of Amendment 

Except with respect to the modifications expressly implemented in accordance herewith, the contents of this Amendment
No. 2 shall not in any way be interpreted as modifying the terms and conditions of the Purchase Agreement and it contains no other modification, whether implicit or ancillary and no other change in any other respect. 

ARTICLE 3 
 GENERAL

  

	3.1	 Shareholders Representative 

The Shareholders’ Representative represents and warrants to the Buyer and to Meridian Bioscience, Inc. that (i) it
has not renounced or otherwise terminated the mandate given to it in the Purchase Agreement to represent the Shareholders as set forth in the Purchase Agreement and (ii) it has not received any notice from any Shareholder that such Shareholder
has or will renounce the mandate given by it in the Purchase Agreement to the Shareholders’ Representative, and that accordingly the Shareholders’ Representative has the right to bind the Shareholders for the purposes set forth in this
Amendment No. 2. 
  

	3.2	 Further Assurances 

Each of the parties hereto shall from time to time execute and deliver all such further documents and instruments and do all
acts and things as another party may reasonably require in connection with this Amendment No. 2 to effectively carry out or better evidence or perfect the full intent and meaning of this Amendment No. 2. 

  
 - 8 - 

	3.3	 Successors, Assigns and Assignment 

This Amendment No. 2 will enure to the benefit of and be binding upon the respective successors and permitted assigns of
the parties hereto. This Amendment No. 2 may not be assigned by any party other than in compliance with and concurrently with the Purchase Agreement. 
  

	3.4	 Amendments and Waivers 

No amendment of this Amendment No. 2 or further amendment to the Purchase Agreement shall be valid or binding unless set
forth in writing and duly executed by all parties hereto. No waiver of any breach of any provision of this Amendment No. 2 shall be effective or binding unless made in writing and signed by the party purporting to give same and, unless
otherwise provided, will be limited to the specific breach waived. 
  

	3.5	 Governing Law and Forum 

(a)     This Amendment No. 2 shall be governed by and construed in accordance with the internal laws
of the Province of Quebec and the federal laws of Canada applicable therein and shall be treated in all respects, as a Quebec contract. 

(b)    Any legal suit, action or proceeding arising out of or based upon this Amendment No. 2 shall
be heard and determined by the courts of the province of Quebec, district of Montreal. 
  

	3.6	 Severability 

If any provision of this Amendment No. 2 is determined by a court of competent jurisdiction to be invalid, illegal or
unenforceable in any respect, such determination shall not impair or affect the validity, legality or enforceability of the remaining provisions hereof, and each provision is hereby declared to be separate, severable and distinct. 

 

	3.7	 Counterparts 

This Amendment No. 2 may be executed in one or more counterparts, each of which shall conclusively be deemed to be an
original but all of which taken together shall be deemed to constitute one and the same agreement. A facsimile transmission of this Amendment No. 2 bearing a signature on behalf of a party shall be legal and binding on such Party. 

 

	3.8	 Language 

The parties hereto acknowledge that they have required that this Amendment No. 2 and all related documents be drawn up in
English. Les parties aux présentes reconnaissent avoir exigé que le présent amendement et tous les documents connexes soient rédigés en anglais. 

(Remainder of this page left blank intentionally; Signature Pages Follow) 

  
 - 9 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2 to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

			
	SELLER:
	
	APRÈS-DEMAIN DIAGNOSTICS INC.
	
	By: /s/ Patrice Allibert                             
       
	Name:	 	Patrice Allibert                                  
  
	Title:	 	President and CEO

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2 to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

	
	BUYER:
	
	MERIDIAN BIOSCIENCE CANADA INC.
	
	By: /s/ Jack Kenny                                
          
	Name: Jack Kenny
	Title: Director

  
 - 11 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2 to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

	
	MERIDIAN PARENTCO:
	
	MERIDIAN BIOSCIENCE, INC.
	
	By: /s/ Jack Kenny                                
         
	Name: Jack Kenny
	Title: Chief Executive Officer

  
 - 12 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2 to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

			
	SHAREHOLDER’S REPRESENTATIVE:
	
	 APRÈS-DEMAIN SA
	
	 By: /s/ Thierry Mauvernay                            

	 Name:	 	Thierry Mauvernay                            
	 Title:	 	President

  
 - 13 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]